Zealand Pharma A/S (ZEAL) 2020年年度报告「NASDAQ」.pdf

1、Growing as a leader in peptide therapeuticsCompany reg.no.20045078Zealand Pharma Annual Report 2020About Zealand PharmaWe intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other rare disease areas with significant unmet medical needs2Zealand Pharma

2、Annual Report 2020Overview 4Zealand Pharma in short 5Financial and sustainability highlights 6Letter from the Chairman 7Letter from the CEO 92020 Achievements 12Consolidated key figures 132021 Outlook and objectives 14Zealand Pharmas first independent launch 15Established US Platform 17Leveraging ma

3、rket presence 19Five in 25 21Zealand Pharmas R&D platform and pipeline 22Peptide platform and pre-clinical programs 23Pre-Clinical Programs 25Clinical Pipeline Overview 27Three patient stories 28Severe Hypoglycemia in diabetes 29Congenital Hyperinsulinism 31Type 1 Diabetes management 34Other Hypogly

4、cemic conditions 35Obesity/Type 2 Diabetes 36Short bowel syndrome 37Corporate matters 40Corporate governance 41Corporate responsibility 44Our People and culture 46Risk management and internal control 48Financial review 50Shareholder information 53Board of Directors 55Corporate Management 58Financial

5、 statementsConsolidated financial statements 60Income statement 62Statement of comprehensive income 62Statement of financial position 63Statement of cash flows 64Statement of changes in equity 64Business overview 65Notes 66Financial statements of the parent company 100Income statement 101Statement o

6、f comprehensive income 101Statement of financial position 102Statement of cash flows 103Statement of changes in equity 103Notes 104Alternative performance measures for the group(non-audited)117Statement of the Board of Directors and Executive Management 118Independent auditors report 119Other inform